Next 10 |
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS PR Newswire SYDNEY , May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased t...
2024-04-05 10:30:00 ET April 5, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies offer therapies for cancer, eye di...
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases PR Newswire SYDNEY , March 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is ...
Kazia announces presentation of new data at AACR Annual Meeting PR Newswire SYDNEY , March 13, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both i...
2024-02-21 10:31:03 ET More on Kazia Kazia Therapeutics falls after announcing $2M direct offering Kazia stock jumps after proposed license deal for paxalisib outside oncology Financial information for Kazia Read the full article on Seeking Alpha For ...
2024-02-21 08:38:39 ET DENVER, Colo., 21 Feb, 2024 (www.247marketnews.com)- Kazia Therapeutics Limited (NASDAQ: KZIA ) reported an early conclusion, based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial, on its investig...
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint PR Newswire Paxalisib plus Radiotherapy Data Shows Promise for Treating Patients with PI3K Pathway Mutation Brain Metastases SYDNEY , Feb. 21, 2024 /PRNewswi...
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS PR Newswire SYDNEY , Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-12-31 MedAvail Holdings Inc. (MDVL) is expected to report for Q3 2023 Nobility Homes, Inc. (NOBH) is expected to report for quarter end 2023-10-31 Walgreens Boots Alliance Inc. (WBA) is expected to report $0.66 for Q1 ...
Disco Corporation ADR (DSCSY) is expected to report for Q2 2024 Sonic Foundry Inc. (SOFO) is expected to report for quarter end 2023-09-30 Sono Group N.V. (SEVCQ) is expected to report for quarter end 2023-09-30 Minim Inc (MINM) is expected to report for Q3 2023 Enel Spa ADR (ENLA...
News, Short Squeeze, Breakout and More Instantly...
Kazia Therapeutics Limited Company Name:
KZIA Stock Symbol:
NASDAQ Market:
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS PR Newswire SYDNEY , May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased t...
Shares of NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-q...